Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

Journal of Medicinal Chemistry

Volumn 41, Issue 4, 1998, Pages 602-617

  Kempf, Dale J ^a   Sham, Hing L ^a   Marsh, Kennan C ^a   Flentge, Charles A ^a   Betebenner, David ^a   Green, Brian E ^a   McDonald, Edith ^a   Vasavanonda, Sudthida ^a   Saldivar, Ayda ^a   Wideburg, Norman E ^a   Kati, Warren M ^a   Ruiz, Lisa ^a   Zhao, Chen ^a   Fino, Lynnmarie ^a   Patterson, Jean ^a   Molla, Akhteruzzaman ^a   Plattner, Jacob J ^a   Norbeck, Daniel W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 77003; A 80987; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR;

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONKEY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; VIRUS INFECTION; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; METABOLIC CLEARANCE RATE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PYRIDINES; RATS; RECOMBINANT PROTEINS; RITONAVIR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0008583584     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970636+     Document Type: Article

References (56)

1. Debouck, C.; Gorniak, J. G.; Strickler, J. E.; Meek, T. D.; Metcalf, B. W.; Rosenberg, M. Human Immunodeficiency Virus Protease Expressed in Escherichia coli Exhibits Autoprocessing and Specific Maturation of the gag Precursor. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 8903-8906.
2. Graves, M. C.; Lim, J. J.; Heimer, E. P.; Kramer, R. A. An 11-kDa Form of Human Immunodeficiency Virus Protease Expressed in Escherichia coli is Sufficient for Enzymic Activity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 2449-2453.
3. Darke, P. L.; Nutt, R. F.; Brady, S. F.; Garsky, V. M.; Ciccarone, T. M.; Leu, C.-T.; Lumma, P. K.; Freidinger, R. M.; Veber, D. F.; Sigal, I. S. HIV-1 Protease Specificity of Peptide Cleavage is Sufficient for Processing of gag and pol Polyproteins. Biochem. Biophys. Res. Commun. 1988, 156, 297.
4. Gottlinger, H. G.; Sodroski, J. G.; Haseltine, W. A. Role of Capsid Precursor Processing and Myristoylation in Morphogenesis and Infectivity of Human Immunodeficiency Vims Type 1- Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 5781-5785.
5. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
6. Le Grice, S. F.; Mills, J.; Mous, J. Active Site Mutagenesis of the AIDS Virus Protease and its Alleviation by trans Complementation. EMBO J. 1988, 7, 2547-2553.
7. Kempf, D.; Sham, H. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246.
8. West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease - a Test of Drug Design Methodologies. Trends Pharm. Sci. 1995, 16, 67-75.
9. Thaisrivongs, S. HIV Protease Inhibitors. Annu. Rep. Med. Chem. 1994, 29, 133-144.
10. Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454.
11. Pearl, L. H.; Taylor, W. R. Sequence Specificity of Retroviral Proteases. Nature 1987, 328, 482.
12. Navia, M. A.; Fitzgerald, P. M. D.; McKeever, B. M.; Leu, C.-T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-Dimensional Structure of Aspartyl Protease from Human Immunodeficiency Virus HIV-1. Nature 1989, 337, 615-620.
13. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B. K; Baldwin, E.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schneider, J.; Kent, S. B. H. Conserved Folding in Retroviral Proteases: Crystal Structure of a Synthetic HIV-1 Protease. Science 1989, 245, 616-621.
14. Holloway, M. K.; Wai, J. M. Structure-Based Design of Human Immunodeficiency Virus-1 Protease Inhibitors-Correlating Calculated Energy With Activity. ACS Symp. Ser. 1995, 589, 36-50.
15. Erickson, J.; Kempf, D. J. Structure-Based Design of Symmetric Inhibitors of HIV-1 Protease. Arch. Virol. 1994, 9, 19-29.
16. Clare, M. HIV Protease: Structure-Based Design. Perspect. Drug Discovery Des. 1993, 1, 49-68.
17. Wlodawer, A.; Erickson, J. W. Structure-Based Inhibitors of HIV-1 Protease. Annu. Rev. Biochem. 1993, 62, 543-585.
18. Ptattner, J. J.; Norbeck, D. W. Obstacles to Drug Development from Peptide Leads. In Drug Discovery Technologies; Clark, R., Moos, W. H., Eds.; Ellis Horwood Ltd.: Chichester, 1990; pp 92-126.
19. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X.-P.; Wideburg, N. E.; Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. ABT-538 is a Potent Inhibitor of Human Immunodeficiency Virus Protease and has High Oral Bioavailability in Humans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2484-2488.
20. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096-4100.
21. Kalish, V.; Kaldor, S.; Shetty, B.; Tatlock, J.; Davies, J.; Hammond, M.; Dressman, B.; Fritz, J.; Appelt, K; Reich, S.; Musick, L.; Wu, B.-W.; Su, K. Iterative Protein Structure-Based Drug Design and Synthesis of HIV Protease Inhibitors. Eur. J. Med. Chem. 1995, 30, S 201-S 214.
22. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal Structure of HIV-1 Protease in Complex With VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
23. 2 Symmetrie Inhibitors of HIV Protease. J. Med. Chem. 1990, 33, 2687-2689.
24. Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; Marsh, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol. J. Med. Chem. 1993, 36, 320-330.
25. 2-Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease. Antimicrob. Agents Chemother. 1991, 35, 2209-2214.
26. 2 Symmetry-Based Human Immunodeficiency Virus Protease Inhibitor. Antimicrob. Agents Chemother. 1995, 39, 1559-1564.
27. Kempf, D. J. Design of Symmetry-Based, Peptidomimetic Inhibitors of HIV Protease. Methods Enzymol. 1994, 241, 334-354.
28. Ho, D. D.; Neumann, A. U.; Perelson, A. S.; Chen, W.; Leonard, J. M.; Markowitz, M. Rapid Turnover of Plasma Virions and CD4 Lymphocytes In HIV-1 Infection. Nature 1995, 373, 123-126.
29. Wei, X.; Ghosh, S. K.; Taylor, M. E.; Johnson, V. A.; Emini, E. A.; Deutsch, P.; Lifson, J. D.; Bonhoeffer, S.; Nowak, M. A.; Hahn, B. H.; Saag, M. S.; Shaw, G. M. Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection. Nature 1995, 373, 117-122.
30. Danner, S. A.; Carr, A.; Leonard, J. M.; Lehman, L. M.; Gudiol, F.; Gonzales, J.; Raventos, A.; Rubio, R.; Bouza, E.; Pintado, V.; Aguado, A. G.; De Lomas, J. G.; Delgado, R.; Borleffs, J. C. C.; Hsu, A.; Valdes, J. M.; Boucher, C. A. B.; Cooper, D. A.; Gimeno, C.; Clotet, B.; Tor, J.; Ferrer, E.; Martinez, P. L.; Moreno, S.; Zancada, G.; Alcami, J.; Noriega, A. R.; Pulido, F.; Glassman, H. N. A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease. N. Engl. J. Med. 1995, 333, 1528-1533.
31. Markowitz, M.; Saag, M.; Powderly, W. G.; Hurley, A. M.; Hsu, A.; Valdes, J. M.; Henry, D.; Sattler, F.; La Marca, A.; Leonard, J. M.; Ho, D. D. A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection. N. Engl. J. Med. 1995, 333, 1534-1539.
32. Heath-Chiozzi, M.; Leonard, J.; Sun, E.; Lehman, L.; Henry, D.; Kravcik, S.; Mills, R.; Potthoff, A. The Advanced HIV Ritonavir Study Group; Cameron, D. W. Ritonavir Clinical Benefit Correlates with HIV RNA and CD4 Cell Levels in Advanced HIV Illnesss. XI International Conference on AIDS, Vancouver, Canada, June 1996, Abstract We.B.3127.
33. Kempf, D. J.; Marsh, K. C.; Fino, L. C.; Bryant, P.; Craig. Kennard, A.; Sham, H. L.; Zhao, C.; Vaaavanonda, S.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Green, B. E.; Herrin, T.; Norbeck, D. W. Design of Orally Bioavailable, Symmetry-Based Inhibitors of HIV Protease. Bioorg. Med. Chem. 1994, 2, 847-858.
34. Ghosh, A. K.; McKee, S. P.; Thompson, W. J.; Darke, P. L.; Zugay, J. C. Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic. J. Org. Chem. 1993, 58, 1025-1029.
35. '(35) Stuk, T. L.; Haight, A. R.; Scarpetti, D.; Allen, M. S.; Menzia, J. A.; Robbins, T. A.; Parekh, S. I.; Langridge, D. C.; Tien, J.-H. J.; Pariza, R. J.; Kerdesky, F. A. J. An Efficient Stereocontrolled Strategy for the Synthesis of Hydroxyethylene Dipeptide Isosteres. J. Org. Chem. 1994, 59, 4040-4041.
36. Matayoshi, E. D.; Wang, G. T.; Krafft, G. A.; Erickson, J. Novel Fluorogenic Substrates for Assaying Retroviral Proteases by Resonance Energy Transfer. Science 1990, 247, 954-958.
37. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds. J. Virol. Methods 1988, 20, 309-321.
38. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Kröhn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Rational Design of Peptide-Based HIV Proteinase Inhibitors. Science 1990, 248, 358-361.
39. Molla, A.; Korneyeva, M.; Gao, Q.; Vasavanonda, S.; Schipper, P. J.; Mo, H.-M.; Markowitz, M.; Chernyavskiy, T.; Niu, P.; Lyons, N.; Hsu, A.; Granneman, G. R.; Ho, D. D.; Boucher, C. A. B.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Ordered Accumulation of Mutations in HIV Protease Confers Resistance to Ritonavir. Nature Med. 1996, 2, 760-766.
40. Kempf, D. J. Progress in the Discovery of Orally Bioavailable Inhibitors of HIV Protease. Perspect. Drug Discovery Des. 1995, 2, 427-436.
41. Deniasen, J.; Marsh, K.; Grabowski, B.; Johnson, M. Metabolism and Disposition of the HIV Protease Inhibitor A-77003. Pharm. Res. 1993, 10, S-376.
42. Kaplan, A.; Michael, S.; Wehbie, R.; Knigge, M.; Paul, D.; Everitt, L.; Kempf, D.; Norbeck, D.; Erickson, J.; Swanstrom, R. Selection of Multiple Human Immunodeficiency Virus Type 1 Variants which Encode Viral Proteases with Decreased Sensitivity to an Inhibitor of the Viral Protease. Proc. Nail Acad. Sci. U.S.A. 1994, 91, 5597-5601.
43. 2 Symmetry-Based Inhibitors of HIV-1 Protease. J. Am. Chem. Soc. 1994, 116, 847-855.
44. Kumar, G. N.; Grabowski, B.; Lee, R.; Denissen, J. F. Hepatic Drug-Metabolizing Activities in Rats after 14 Days of Oral Administration of the Human Immunodeficiency Virus-Type 1 Protease Inhibitor Ritonavir (ABT-538). Drug Metab. Dispos. 1996, 24, 615-617.
45. Kempf, D. J.; Marsh, K. C.; Kumar, G.; Rodrigues, A. D.; Denissen, J. F.; McDonald, E.; Kukulka, M. J.; Hsu, A.; Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Plattner, J. J.; Norbeck, D. W.; Leonard, J. M. Pharmacokinetic Enhancement of Inhibitors of the Human Immunodeficiency Virus Protease by Coadministration with Ritonavir. Antimicrob. Agents Chemother. 1997, 41, 654-660.
46. Hungate, R. W.; Chen, J. L.; Starbuck, K. E.; Vacca, J. P.; McDaniel, S. L.; Levin, R. B.; Dorsey, B. D.; Guare, J. P.; Holloway, M. K.; Whitter, W.; Darke, P. L.; Zugay, J. A.; Schleif, W. A.; Emini, E. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Anderson, P. S.; Huff, J. R. Synthesis, Antiviral Activity and Bioavailability Studies of γ-Lactam Derived HIV Protease Inhibitors. Bioorg. Med. Chem. 1994, 2, 859-879.
47. Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen, I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor. J. Med. Chem. 1994, 37, 3443-3451.
48. Kempf, D. J.; Molla, A.; Marsh, K. C.; Park, C.; Rodrigues, A. D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Flentge, C. A.; Muchmore, S.; Wideburg, N. E.; Saldivar, A.; Cooper, A.; Kati, W. M.; Stewart, K. D.; Norbeck, D. W. Lack of Stereospecificity in the Binding of the P2 Amino Acid of Ritonavir to HIV Protease. Bioorg. Med. Chem. Lett 1997, 7, 699-704.
49. Kageyama, S.; Anderson, B. D.; Hoesterey, B. L.; Hayashi, H.; Kiso, Y.; Flora, K. P.; Mitsuya, H. Protein Binding of Human Immunodeficiency Virus Protease Inhibitor KNI-272 and Alteration of its In Vitro Antiretroviral Activity in the Presence of High Concentrations of Proteins. Antimicrob. Agents Chemother. 1994, 38, 1107-1111.
50. Bilello, J. A.; Bilello, P. A.; Prichard, M.; Robins, T.; Drusano, G. L. Reduction of the In Vitro Activity of A77003, an Inhibitor of Human Immunodeficiency Virus Protease, by Human Serum ai Acid Glycoprotein. J. Infect. Dis. 1995, 171, 546-551.
51. Markowitz, M.; Cao, Y.; Vesanen, M.; Talal, A.; Nixon, D.; Hurley, A.; O'Donovan, R.; Racz, P.; Tenner-Racz, K.; Ho, D. D. Recent HIV Infection Treated with AZT, 3TC, and a Potent Protease Inhibitor. 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., Jan 22-26, 1997, Abstract LB8.
52. Cohen, C.; Sun, E.; Cameron, W.; McMahon, D.; Parthing, C.; Poretz, D.; Markowitz, M.; Follansbee, S.; Mellors, J.; Ho, D.; Hsu, A.; Maki, R.; Salgo, M.; Leonard, J. Ritonavir-Saquinavir Combination Treatment in HIV-Infected Patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, Sept 15-18, 1996, Abstract LB7b.
53. Mashraqui, S. H.; Keehn, P. M. Cyclophanes. 14. Synthesis, Structural Assignment, and Conformational Properties of [2.2](2,5)Oxazolo and Thazolophanes. J. Am. Chem. Soc. 1982, 104, 4461-4465.
54. Schöllkopf, U.; Schröde, R. 2-Unsubstituted Oxazoles from a-Metalated Isocyanides and Acylating Agents. Angew. Chem., Int. Ed. Engl. 1971, 10, 333.
55. Kanemasa, S.; Asai, Y.; Tanaka, J. Synthesis of Substituted Pyridines by a Cycloaddition Route Using Nitrile Oxides and Homoallyl Alcohols. Bull. Chem. Soc. Jpn. 1991, 64, 375-380.
56. Yokokawa, F.; Hamada, Y.; Shioiri, T. Synthesis of 2,4-Disubstituted Oxazoles. Synlett 1992, 153.